4D MOLECULAR THERAPEUTICS IN (FDMT) Stock Fundamental Analysis
USA - NASDAQ:FDMT - US35104E1001 - Common Stock
10.5 USD
-0.42 (-3.85%)
10.5 USD
0 (0%)
Taking everything into account, FDMT scores 3 out of 10 in our fundamental rating. FDMT was compared to 535 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for FDMT as it has an excellent financial health rating, but there are worries on the profitability. FDMT has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
FDMT had negative earnings in the past year.
FDMT had a negative operating cash flow in the past year.
In the past 5 years FDMT always reported negative net income.
In the past 5 years FDMT always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -41.41%, FDMT perfoms like the industry average, outperforming 58.43% of the companies in the same industry.
FDMT has a Return On Equity of -46.60%. This is in the better half of the industry: FDMT outperforms 67.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.41% | ||
| ROE | -46.6% | ||
| ROIC | N/A |
ROA(3y)-33.14%
ROA(5y)-27.85%
ROE(3y)-36.91%
ROE(5y)-31.04%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FDMT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
FDMT does not have a ROIC to compare to the WACC, probably because it is not profitable.
FDMT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, FDMT has more shares outstanding
FDMT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 2.94 indicates that FDMT is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.94, FDMT is in the better half of the industry, outperforming 70.04% of the companies in the same industry.
FDMT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.94 |
ROIC/WACCN/A
WACC8.75%
2.3 Liquidity
A Current Ratio of 8.75 indicates that FDMT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.75, FDMT is in the better half of the industry, outperforming 76.97% of the companies in the same industry.
FDMT has a Quick Ratio of 8.75. This indicates that FDMT is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of FDMT (8.75) is better than 76.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.75 | ||
| Quick Ratio | 8.75 |
3. Growth
3.1 Past
The earnings per share for FDMT have decreased strongly by -54.82% in the last year.
The Revenue for FDMT has decreased by -99.92% in the past year. This is quite bad
Measured over the past years, FDMT shows a very negative growth in Revenue. The Revenue has been decreasing by -64.95% on average per year.
EPS 1Y (TTM)-54.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55.56%
Revenue 1Y (TTM)-99.92%
Revenue growth 3Y-87.29%
Revenue growth 5Y-64.95%
Sales Q2Q%200%
3.2 Future
The Earnings Per Share is expected to decrease by -7.85% on average over the next years.
FDMT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 130.91% yearly.
EPS Next Y-26.44%
EPS Next 2Y-12.42%
EPS Next 3Y-10.64%
EPS Next 5Y-7.85%
Revenue Next Year105.44%
Revenue Next 2Y47.6%
Revenue Next 3Y40.14%
Revenue Next 5Y130.91%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for FDMT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FDMT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
FDMT's earnings are expected to decrease with -10.64% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.42%
EPS Next 3Y-10.64%
5. Dividend
5.1 Amount
FDMT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
10.5
-0.42 (-3.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners86.98%
Inst Owner Change0%
Ins Owners3.85%
Ins Owner Change-0.3%
Market Cap490.35M
Revenue(TTM)33.00K
Net Income(TTM)-196.14M
Analysts81.25
Price Target31.04 (195.62%)
Short Float %9.41%
Short Ratio5.79
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.75%
Min EPS beat(2)-9.71%
Max EPS beat(2)2.21%
EPS beat(4)1
Avg EPS beat(4)-6.46%
Min EPS beat(4)-10.47%
Max EPS beat(4)2.21%
EPS beat(8)5
Avg EPS beat(8)7.58%
EPS beat(12)8
Avg EPS beat(12)6.75%
EPS beat(16)11
Avg EPS beat(16)5.29%
Revenue beat(2)0
Avg Revenue beat(2)-96.24%
Min Revenue beat(2)-96.41%
Max Revenue beat(2)-96.07%
Revenue beat(4)0
Avg Revenue beat(4)-97.97%
Min Revenue beat(4)-99.94%
Max Revenue beat(4)-96.07%
Revenue beat(8)2
Avg Revenue beat(8)55.45%
Revenue beat(12)2
Avg Revenue beat(12)16.36%
Revenue beat(16)4
Avg Revenue beat(16)46.83%
PT rev (1m)5.74%
PT rev (3m)2.95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.65%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-22.91%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-16.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 14859.09 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.17 | ||
| P/tB | 1.17 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.53
EYN/A
EPS(NY)-3.77
Fwd EYN/A
FCF(TTM)-3.64
FCFYN/A
OCF(TTM)-3.56
OCFYN/A
SpS0
BVpS9.01
TBVpS9.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.41% | ||
| ROE | -46.6% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-33.14%
ROA(5y)-27.85%
ROE(3y)-36.91%
ROE(5y)-31.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 42.91% | ||
| Cap/Sales | 10375.8% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.75 | ||
| Quick Ratio | 8.75 | ||
| Altman-Z | 2.94 |
F-Score2
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)195.17%
Cap/Depr(5y)250.86%
Cap/Sales(3y)3538.16%
Cap/Sales(5y)2134.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-54.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55.56%
EPS Next Y-26.44%
EPS Next 2Y-12.42%
EPS Next 3Y-10.64%
EPS Next 5Y-7.85%
Revenue 1Y (TTM)-99.92%
Revenue growth 3Y-87.29%
Revenue growth 5Y-64.95%
Sales Q2Q%200%
Revenue Next Year105.44%
Revenue Next 2Y47.6%
Revenue Next 3Y40.14%
Revenue Next 5Y130.91%
EBIT growth 1Y-6.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.11%
EBIT Next 3Y-20.55%
EBIT Next 5YN/A
FCF growth 1Y-73.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-78.51%
OCF growth 3YN/A
OCF growth 5YN/A
4D MOLECULAR THERAPEUTICS IN / FDMT FAQ
What is the fundamental rating for FDMT stock?
ChartMill assigns a fundamental rating of 3 / 10 to FDMT.
Can you provide the valuation status for 4D MOLECULAR THERAPEUTICS IN?
ChartMill assigns a valuation rating of 0 / 10 to 4D MOLECULAR THERAPEUTICS IN (FDMT). This can be considered as Overvalued.
How profitable is 4D MOLECULAR THERAPEUTICS IN (FDMT) stock?
4D MOLECULAR THERAPEUTICS IN (FDMT) has a profitability rating of 1 / 10.